Department of Internal Medicine, Division of Nephrology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
Nephrol Dial Transplant. 2012 May;27(5):2101-7. doi: 10.1093/ndt/gfr558. Epub 2011 Sep 29.
Cardiovascular disease is the leading cause of mortality among renal transplant recipients. In the general population, coronary artery calcification (CAC) and progression of CAC are predictors of future cardiac risk. We conducted a study to determine the progression of CAC in renal transplant recipients; we also examined the factors associated with progression and the impact of the analytic methods used to determine CAC progression.
We used multi-detector computed tomography to examine CAC in 150 prevalent renal transplant recipients, who did not have a documented cardiovascular disease. A baseline and a follow-up scan were performed and changes in CAC scores were evaluated in each patient individually, to calculate the incidence of CAC progression. Multivariate logistic regression analysis was used to evaluate the determinants of CAC progression.
Baseline CAC prevalence was 35.3% and the mean CAC score was 60.0 ± 174.8. At follow-up scan that was performed after an average of 2.8 ± 0.4 years, CAC prevalence increased to 64.6% and the mean CAC score to 94.9 ± 245.7. Progression of individual CAC score was found between 28.0 and 38.0%, depending on the method used to define progression. In patients with baseline CAC, median annualized rate of CAC progression was 11.1. Baseline CAC, high triglyceride and bisphosphonate use were the independent determinants of CAC progression.
Renal transplantation does not stop or reverse CAC. Progression of CAC is the usual evolution pattern of CAC in renal transplant recipients. Beside baseline CAC, high triglyceride level and bisphosphonate use were associated with progression of CAC.
心血管疾病是肾移植受者死亡的主要原因。在普通人群中,冠状动脉钙化(CAC)和 CAC 的进展是未来心脏风险的预测指标。我们进行了一项研究,以确定肾移植受者 CAC 的进展情况;我们还研究了与 CAC 进展相关的因素以及用于确定 CAC 进展的分析方法的影响。
我们使用多探测器计算机断层扫描检查了 150 例无心血管疾病记录的现患肾移植受者的 CAC。进行了基线和随访扫描,并对每位患者的 CAC 评分变化进行了评估,以计算 CAC 进展的发生率。使用多变量逻辑回归分析评估 CAC 进展的决定因素。
基线 CAC 的患病率为 35.3%,平均 CAC 评分为 60.0 ± 174.8。在平均 2.8 ± 0.4 年后进行的随访扫描中,CAC 的患病率增加到 64.6%,平均 CAC 评分为 94.9 ± 245.7。根据用于定义进展的方法不同,个体 CAC 评分的进展情况在 28.0%至 38.0%之间。在基线 CAC 的患者中,CAC 进展的中位年率为 11.1。基线 CAC、高甘油三酯和双膦酸盐的使用是 CAC 进展的独立决定因素。
肾移植并不能阻止或逆转 CAC。CAC 的进展是肾移植受者 CAC 的常见演变模式。除了基线 CAC 外,高甘油三酯水平和双膦酸盐的使用与 CAC 的进展有关。